TY - JOUR
T1 - Ocular side-effects associated with imatinib mesylate (Gleevec®)
AU - Fraunfelder, Frederick W.
AU - Solomon, Jonathan
AU - Druker, Brian J.
AU - Esmaeli, Bita
AU - Kuyl, Jennifer
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2003/8
Y1 - 2003/8
N2 - This retrospective case series describes ocular side-effects associated with imatinib mesylate (Gleevec®) and the clinical characteristics of these adverse reactions. A chart review of 104 patients on imatinib mesylate therapy from Oregon Health & Science University's Cancer Center were studied with regard to ocular side-effects. In addition, spontaneous reports from the Food and Drug Administration, the World Health Organization, and the National Registry of Drug-Induced Ocular Side-Effects databases were reviewed, including a Medline literature search. Seventy-three (70%) of the patients at OHSU developed periorbital edema and 19 patients (18%) developed epiphora after receiving imatinib mesylate. Average dose was 407.5 +/-60mg. Periorbital edema occurred an average of 68+/-48 days after initiation of therapy. WHO classification of side-effects is as follows: certain: periorbital edema; probable: epiphora; possible: extraocular muscle palsy, ptosis, blepharoconjunctivitis; unlikely: glaucoma, papilledema, retinal hemorrhage, photosensitivity, abnormal vision, and increased intraocular pressure. Periorbital edema and epiphora are the two most common ocular side-effects related to imatinib mesylate therapy. Clinical characteristics of imatinib mesylate induced periorbital edema are described. Management of ocular side-effects is conservative except in very rare cases of visually significant periorbital edema.
AB - This retrospective case series describes ocular side-effects associated with imatinib mesylate (Gleevec®) and the clinical characteristics of these adverse reactions. A chart review of 104 patients on imatinib mesylate therapy from Oregon Health & Science University's Cancer Center were studied with regard to ocular side-effects. In addition, spontaneous reports from the Food and Drug Administration, the World Health Organization, and the National Registry of Drug-Induced Ocular Side-Effects databases were reviewed, including a Medline literature search. Seventy-three (70%) of the patients at OHSU developed periorbital edema and 19 patients (18%) developed epiphora after receiving imatinib mesylate. Average dose was 407.5 +/-60mg. Periorbital edema occurred an average of 68+/-48 days after initiation of therapy. WHO classification of side-effects is as follows: certain: periorbital edema; probable: epiphora; possible: extraocular muscle palsy, ptosis, blepharoconjunctivitis; unlikely: glaucoma, papilledema, retinal hemorrhage, photosensitivity, abnormal vision, and increased intraocular pressure. Periorbital edema and epiphora are the two most common ocular side-effects related to imatinib mesylate therapy. Clinical characteristics of imatinib mesylate induced periorbital edema are described. Management of ocular side-effects is conservative except in very rare cases of visually significant periorbital edema.
UR - http://www.scopus.com/inward/record.url?scp=0041971163&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0041971163&partnerID=8YFLogxK
U2 - 10.1089/108076803322279426
DO - 10.1089/108076803322279426
M3 - Article
C2 - 12964961
AN - SCOPUS:0041971163
SN - 1080-7683
VL - 19
SP - 371
EP - 375
JO - Journal of Ocular Pharmacology and Therapeutics
JF - Journal of Ocular Pharmacology and Therapeutics
IS - 4
ER -